Annotation Detail
Information
- Associated Genes
- CDKN2A
- Associated Variants
-
CDKN2A MUTATION
CDKN2A MUTATION - Associated Disease
- cholangiocarcinoma
- Source Database
- CIViC Evidence
- Description
- In a phase 2 trial, patients with gallbladder cancer or bile duct cancer with CDKN2A loss or mutation were received palbociclib. Among 10 patients, no overall response or stable disease at 16 weeks were observed.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/7300
- Gene URL
- https://civic.genome.wustl.edu/links/genes/14
- Variant URL
- https://civic.genome.wustl.edu/links/variants/2704
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Cholangiocarcinoma
- Evidence Direction
- Does Not Support
- Drug
- Palbociclib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Palbociclib | Sensitivity | false |